Endocrinology Advisor3d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Interesting Engineering on MSN4d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Medscape4d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
U.S. News & World Report3d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...
Monthly Prescribing Reference5d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The rapid-acting insulin should be administered subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm. The dosage is based on the patient’s ...
The Bryan Times3d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Sierra Sun Times5d
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...
Tyler Morning Telegraph4d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the FDA. Administering Merilog subcutaneously five to 10 minutes before mealtime ...